Journal: Frontiers in Cell and Developmental Biology

Article Title: PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3

doi: 10.3389/fcell.2020.598205

Figure Lengend Snippet: Loss of PD-L1 Induces Cell proliferation and Triggers EMT in Aggressive EC Cells. (A) Western blotting analysis of PD-L1 and MCL-1 expression in SPAC-1-L cells overexpressing PD-L1, and in PD-L1-silenced HEC-50 cells. (B) Cellular morphology of HEC-50 cells after knockdown of PD-L1. Scale bar, 100 μm. (C–E) Proliferation (C) , wound-healing (D) , and invasion (E) assays in EC cells after overexpression or knockdown of PD-L1. (F) A heatmap showing gene expression levels in human aggressive EC cell lines (Expression Atlas database). (G,H) Examination of gene expression in HEC-50 cells after knockdown of PD-L1 (G) and in SPAC-1-L cells after overexpression of PD-L1 (H) was performed using qRT-PCR assays. VIM, Vimentin. ∗ P < 0.05.

Article Snippet: The PD-L1 cDNA expresion vector pCMV6-PD-L1 (PD-L1-vec, RC213071), the MCL-1 cDNA expression vector pCMV6-MCL-1 (MCL-1-vec, RC200521), the MEG3 expression vector pCMV6-MEG3 (MEG3-vec, SC105816) and the pCMV6 control vector (Ctr-vec, PS100001) were purchased from OriGene (Rockville, MD, United States).

Techniques: Western Blot, Expressing, Over Expression, Quantitative RT-PCR

Journal: Frontiers in Cell and Developmental Biology

Article Title: PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3

doi: 10.3389/fcell.2020.598205

Figure Lengend Snippet: PD-L1 Represses EMT by Decreasing MCL-1 Expression. (A) PD-L1-silenced HEC-50 cells or control cells were transfected with (or without) MCL-1 siRNA, and MCL-1 mRNA expression was verified using qRT-PCR analysis. (B) Cellular morphology of HEC-50 cells shown in panel (A) . Scale bar, 100 μm. (C) Wound-healing and invasion assays in HEC-50 cells transfected as indicated. (D) Western blotting analysis of the indicated proteins in HEC-50 cells transfected as indicated. (E) The IHC staining results were obtained from the HPA database. Immunohistochemical staining of EC tissues from the same patient showed a high MCL-1 and HSP47 expression and a low ZO-1 expression in EC tissues. (F) The correlation between the indicated genes and overall survival in patients with EC (KM plotter database). ∗ P < 0.05.

Article Snippet: The PD-L1 cDNA expresion vector pCMV6-PD-L1 (PD-L1-vec, RC213071), the MCL-1 cDNA expression vector pCMV6-MCL-1 (MCL-1-vec, RC200521), the MEG3 expression vector pCMV6-MEG3 (MEG3-vec, SC105816) and the pCMV6 control vector (Ctr-vec, PS100001) were purchased from OriGene (Rockville, MD, United States).

Techniques: Expressing, Transfection, Quantitative RT-PCR, Western Blot, Immunohistochemistry, Immunohistochemical staining, Staining

Journal: Frontiers in Cell and Developmental Biology

Article Title: PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3

doi: 10.3389/fcell.2020.598205

Figure Lengend Snippet: Model Summarizing the Role of MEG3, MiR-216a, PD-L1, and MCL-1 in Controlling the Proliferative and Invasive Potential of aggressive EC cells. The downregulation of MEG3 causes an elevation of miR-216a expression. By targeting the 3′-UTR of PD-L1 mRNA, miR-216a suppresses PD-L1 expression. PD-L1 serves as a tumor-suppressor to inhibit the proliferation, EMT and invasive potential of aggressive EC cells via repressing MCL-1 expression.

Article Snippet: The PD-L1 cDNA expresion vector pCMV6-PD-L1 (PD-L1-vec, RC213071), the MCL-1 cDNA expression vector pCMV6-MCL-1 (MCL-1-vec, RC200521), the MEG3 expression vector pCMV6-MEG3 (MEG3-vec, SC105816) and the pCMV6 control vector (Ctr-vec, PS100001) were purchased from OriGene (Rockville, MD, United States).

Techniques: Expressing